Spots Global Cancer Trial Database for AG-120 in People With IDH1 Mutant Chondrosarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: AG-120 in People With IDH1 Mutant Chondrosarcoma
Official Title: Phase II Study of AG-120 in IDH1 Mutant Chondrosarcoma
Study ID: NCT04278781
Interventions
Study Description
Brief Summary: This study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Johns Hopkins Hospital (Data Collection Only), Baltimore, Maryland, United States
Columbia University (Specimen Analysis Only), New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
The Ohio State University (Data Collection Only), Columbus, Ohio, United States
MD Anderson Cancer Center (Data Collection Only), Houston, Texas, United States
Contact Details
Name: Ciara M Kelly, MBBCh, BAO
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
